A new genomic test can help predict whether men are more likely to harbor an aggressive form of prostate cancer, according to a new UCSF study.
May 08, 2013
December 11, 2012
President Barack Obama announced his intent to nominate UCSF's Mack Roach, who is recognized as a major authority on the treatment of prostate cancer, to the National Cancer Advisory Board.
February 22, 2012
Uncovering the network of genes regulated by a crucial molecule involved in cancer called mTOR, which controls protein production inside cells, researchers at UCSF have discovered how a protein “master regulator” goes awry, leading to metastasis, the fatal step of cancer.
February 01, 2012
Scientists at UCSF have identified nearly 200 genes in the healthy prostate tissue of men with low-grade prostate cancer that may help explain how physical activity improves survival from the disease.
October 25, 2011
New studies of vitamin supplements, prostate cancer risk in men and mortality in women have yielded disappointing results. Some researchers remain optimistic about identifying dietary and lifestyle interventions that are beneficial to health.
October 19, 2011
A rekindled controversy over the use of PSA screening to help detect prostate cancer highlights the different perspectives physicians may take in framing issues, evaluating studies and deciding on best practices.
September 01, 2011
For the first time in his life, 50-year-old Art Wagner is growing a beard to raise awareness of prostate cancer after he was successfully treated at UCSF Medical Center.
May 24, 2011
A study of 1,455 U.S. men diagnosed with early-stage prostate cancer has found a link between brisk walking and lowered risk of prostate cancer progression, according to scientists at UCSF and the Harvard School of Public Health.
August 05, 2010
Surgery for localized prostate cancer offers a significantly higher survival rate than either external-beam radiation or hormonal therapies, according to a new study led by researchers at UCSF.
May 21, 2010
The cancer vaccine sipuleucel-T -- now commercially branded as Provenge -- will soon be available at a select group of medical centers nationwide, including UCSF.